In collaboration with Merck, the intravenous formulation of Cardiome's lead molecule, vernakalant (IV), was granted marketing approval in September, 2010 in the European Union, Iceland and Norway under the trademark BRINAVESSTM for rapid conversion of recent onset AF to sinus rythm in adults. It continues to expand into new markets around the world. + READ MORE
11 August, 2014
Cardiome Reports Second Quarter 2014 Financial Results
6 August, 2014
Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access
Cardiome is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems.